Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma

References

• Abbott KC, Agodoa LY. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol. 2001;56(3):207–210.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33.
   PubMed Web of Science ®Google Scholar
• Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol. 2000;65(3):175–181.
   PubMed Web of Science ®Google Scholar
• Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48(2):337–341.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Anagnostopoulos A, Roussou M, et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica. 2007;92(4):546–549.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Zervas K, Symeonidis A, et al. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia. 2009;23(6):1152–1157.
   PubMed Web of Science ®Google Scholar
• Reule S, Sexton DJ, Solid CA, et al. ESRD due to multiple myeloma in the United States, 2001–2010. JASN. 2016;27(5):1487–1494.
   Web of Science ®Google Scholar
• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335(2):91–97.
   PubMed Web of Science ®Google Scholar
• Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875–1883.
   PubMed Web of Science ®Google Scholar
• Waszczuk-Gajda A, Lewandowski Z, Drozd-Sokolowska J, et al. Autologous peripheral blood stem cell transplantation in dialysis-dependent multiple myeloma patients-DAUTOS Study of the Polish Myeloma Study Group. Eur J Haematol. 2018;101(4):475–485.
   PubMed Web of Science ®Google Scholar
• Firkin F, Hill PA, Dwyer K, et al. Reversal of dialysis-dependent renal failure in light-chain deposition disease by autologous peripheral blood stem cell transplantation. Am J Kidney Dis. 2004;44(3):551–555.
   PubMed Web of Science ®Google Scholar
• Mahindra A, Hari P, Fraser R, et al. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplant. 2017;52(12):1616–1622.
   PubMed Web of Science ®Google Scholar
• Augeul-Meunier K, Chretien ML, Stoppa AM, et al. Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. Bone Marrow Transplant. 2018;53(6):749–755.
   PubMed Web of Science ®Google Scholar
• Antlanger M, Dust T, Reiter T, et al. Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. Bmc Cancer. 2018;18(1):1008.
   PubMedGoogle Scholar
• Sweiss K, Culos K, Patel S, et al. Melphalan 200 Mg/m2 in patients with renal impairment is associated with increased short term toxicity but improved response and longer treatment-free survival. Blood. 2015;126(23):1998–1998.
   Web of Science ®Google Scholar
• Knudsen LM, Nielsen B, Gimsing P, et al. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol. 2005;75(1):27–33.
   PubMed Web of Science ®Google Scholar
• Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114(4):822–829.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2007;39(10):605–611.
   PubMed Web of Science ®Google Scholar
• St Bernard R, Chodirker L, Masih-Khan E, et al. Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure. Bone Marrow Transplant. 2015;50(1):95–99.
   PubMed Web of Science ®Google Scholar
• Carlson K. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant. 2005;35(10):985–990.
   PubMed Web of Science ®Google Scholar
• Raab MS, Breitkreutz I, Hundemer M, et al. The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica. 2006;91(11):1555–1558.
   PubMed Web of Science ®Google Scholar
• El Fakih R, Fox P, Popat U, et al. Autologous hematopoietic stem cell transplantation in dialysis-dependent myeloma patients. Cl Lymph Myelom Leuk. 2015;15(8):472–476.
   PubMed Web of Science ®Google Scholar
• Parikh GC, Amjad AI, Saliba RM, et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15(7):812–816.
   PubMed Web of Science ®Google Scholar
• Balsam L, Saad C, Arsene C, et al. Impact of autologous stem cell transplantation on blood pressure and renal function in multiple myeloma patients. J Natl Med Assoc. 2017;109(3):182–191.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Summary of recommendation statements. Kidney Int Suppl. 2013;3(3):263–265.
   Google Scholar
• 2014 International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Nihon Rinsho. 2016;74 (Suppl 5):264–268.
   Google Scholar
• Zagouri F, Kastritis E, Zomas A, et al. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. Eur J Haematol. 2017;99(5):409–414.
   PubMed Web of Science ®Google Scholar
• Jiang J. Linear and generalized linear mixed models and their applications. New York; London: Springer; 2007.
   Google Scholar
• Kaplan EL, Meier P. Nonparametric-estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression Models and Life-Tables. J R Stat Soc B. 1972;34(2):187–202.
   Google Scholar
• Rizopoulos D. JM: an R package for the joint modelling of longitudinal and time-to-event data. J Stat Softw. 2010;35(9):1–33.
   PubMed Web of Science ®Google Scholar
• Buyse M, Piedbois P. On the relationship between response to treatment and survival time. Statist Med. 1996;15(24):2797–2812.
   PubMed Web of Science ®Google Scholar
• Bird JM, Fuge R, Sirohi B, et al. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study. Br J Haematol. 2006;134(4):385–390.
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Lahuerta JJ, Garcia-Sanz R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J. 2000;1(1):28–36.
   PubMedGoogle Scholar
• Waszczuk-Gajda A, Małyszko J, Vesole DH, et al. Negative impact of borderline creatinine concentration and glomerular filtration rate at baseline on the outcome of patients with multiple myeloma treated with autologous stem cell transplant. Transplant Proc. 2020. DOI:10.1016/j.transproceed.2020.02.067.
   Web of Science ®Google Scholar
• Ahmed A, Rich MW, Sanders PW, et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007;99(3):393–398.
   PubMed Web of Science ®Google Scholar
• Perazella MA, Khan S. Increased mortality in chronic kidney disease: a call to action. Am J Med Sci. 2006;331(3):150–153.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. JASN. 2006;17(7):2034–2047.
   Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Cin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar